not generalizable to other RCTs. Goal Attainment Scaling (GAS); Global Measures. Clinician Interview-Based Impression of Change plus caregiver input ( CIBIC. interview [CIBIC-plus]). The ADAS- cog, disease assessment in dementia scale, and neuropsychiatric inventory are recorded by supervising site investigator, but . The Clinician Interview-Based Impression of Change, plus carer interview (CIBIC -Plus), is widely used in antidementia drug trials. It comprises Likert scales for.

Author: Tojakinos Kajizahn
Country: Fiji
Language: English (Spanish)
Genre: Software
Published (Last): 27 December 2005
Pages: 402
PDF File Size: 14.18 Mb
ePub File Size: 17.81 Mb
ISBN: 983-8-66428-420-2
Downloads: 15632
Price: Free* [*Free Regsitration Required]
Uploader: Fezuru

This study aimed to assess the clinically variable ChEI treatment effects in a group of patients with mild AD using a semantic association and an N-back light working memory activation paradigm.

Latha Velayudhan Simon Lovestone. Prospectively defined analyses failed to demonstrate a statistically cibix benefit of memantine treatment compared with placebo on the Severe Impairment Battery SIB at week 24 end point, although a significant advantage was observed for memantine at weeks 12 and Table 1 Summary of baseline demographic characteristics of patients.

CIBIC Plus-J Assessment Using a Videotaped Method in Alzheimer’s Disease Patients

National Center for Biotechnology InformationU. The sites where this method can be conducted are limited, because a sufficiently large room must be available for the videotaping, as well as sufficient time for the videotaping process.

Reliability study on the Japanese version of the clinician’s interview-based impression of change. These enrolled individuals who had completed one of two 3- or 5-month randomized clinical trials parent trials involving patients with mild to moderate Alzheimer’s disease AD.


A placebo-controlled, double-blind, comparative study of Galantamine hydrobromide in patients with Alzheimer-type dementia in Japanese. No secular trend and high variability for ADAS-cog change among placebo groups from clinical trials: Disclosure Statement This report is scals on the data of a clinical trial that was sponsored by Dainippon Sumitomo Pharma Co.

Search Our Scientific Publications & Authors

Author information Copyright and License information Disclaimer. To evaluate the efficacy and safety of rapidly titrated rivastigmine administered twice BID or three times TID daily in patients with mild to moderate Alzheimer’s disease AD.

Whether it is also appropriate for severe AD in Chinese patients remains unknown. Kundel HL, Palansky M.

Video Recording Voices of patients, caregivers, and CIBIC plus-J interviewers were recorded, and facial expressions of patients and caregivers were videotaped. The objective of this review was to consider available efficacy, tolerability, and safety data from studies of ChEIs in PDD. Progressive language impairment is among the primary components of cognitive decline in Alzheimer’s disease AD.

Hallucinations in Alzheimer’s disease AD may indicate greater cortical cholinergic deficits. Patients with Parkinson’s disease dementia PDD often have significant cholinergic defects, which may be treated with cholinesterase inhibitors ChEIs. Epub Jul The efficacy and safety of Fufangdanshen tablets Radix Salviae miltiorrhizae formula tablets for mild to moderate vascular dementia: Development of a functional measure for persons with Alzheimer’s disease: Dement Geriatr Cogn Disord 28;23 2: The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: Curr Alzheimer Res Apr;6 2: Clinical trials of cholinesterase inhibitor ChEI drugs, although generally reporting only minimal improvements in patients with Alzheimer’s disease ADindicate that a subgroup of patients may respond substantially to treatment.


To evaluate efficacy and safety of galantamine for patients with vascular dementia VaD. In fact, tremendous effort was made to understand the dialects of patients and their caregivers in this study.

CIBIC-plus Publications | PubFacts

Fleiss JL, Cohen J. Donepezil has been used worldwide for the treatment of severe Alzheimer’s disease AD. Ciblc entorhinal cortex and the olfactory bulb, critical areas for olfactory function, are rich in acetylcholine, the neurotransmitter implicated in AD pathology and treatment. Combination therapy for patients with Alzheimer disease AD was suggested, but the additional benefit of combination therapy is still controversial.

Investigation of the effects of use of nursing care services on changes of status of nursing care for patients with dementia and consideration of the effect on CIBIC-plus by these changes in Japanese. The global severity scales that have been used include: Arch Neurol Aug 11;68 8: The degeneration of acetylcholine-containing neurons in the basal forebrain has been implicated in the symptoms of AD. While the interrater reliability of CGIC has already been reported, that of the 3 subscales has not.